[Hopespringpcsg] FW: ASCO: 18 Month ADT Enough in High-Risk Prostate Cancer?

[Glen Tolhurst]

Hi all:

Below are several interesting articles relating to PCa.

Thx.

Glen

 

From: Cancer Network [mailto:cancernetwork at email.cmpmedica-usa.com] 

Subject: ASCO: 18 Month ADT Enough in High-Risk Prostate Cancer?

 

Plus: Does ERG expression predict docetaxel benefit in prostate cancer?


To view this email as a web page, click
<http://view.email.cmpmedica-usa.com/?qs=3ee1ff0f72e132cc79b74766b2cb9c40380
137b774511cf65baf10257174b6c3edad2faf41228340535578523abb9137954b9d2e65b9fd9
507c75d13708c87045757ea4aea27980f> here.




 Modern Medicine Network
<http://www.ubmmedica.com/wp-content/uploads/2016/11/ModernMedicineNetwork-s
mall.png> 

 


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2f65821b0b2641ceda4
90016d08194cad3da8faf554b2d8c90e4e22a3d9308ac10743cc447ff6f313> Cancer
Network

 


ASCO 2017   |  June 7, 2017 

 


  



 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a27f94e5e1a582152917
9b4cb147bdfd8e2f0ee0e6420557ab0fb4a966688010394568db50f2ad3389> Prostate
Cancer Highlights From ASCO 2017 


Cancer Network presents exclusive coverage on prostate cancer from the 2017
American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6.
We bring you expert interviews and reports on the latest trials and
scientific advances that are changing the way this malignancy is managed and
treated. 


  


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259
d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4> Reducing ADT
to 18 Months May Be Sufficient in High-Risk Prostate Cancer 


Androgen deprivation therapy can be safely reduced from 36 months to 18
months in high-risk prostate cancer, according to results of a phase III
trial. 


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259
d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4>  Read more  


ADVERTISEMENT 


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef6
0db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab>
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef6
0db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab>
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef6
0db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab>
Advertisement

 


  



  


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33c
ff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b> Does ERG
Expression Predict Docetaxel Benefit in Prostate Cancer? 


Tumor expression of the oncogene ERG might predict patient benefit from
adding docetaxel to androgen deprivation therapy, according to analyses of
two phase III clinical trials. 


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33c
ff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b>  Read more  

 


  



  


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c
05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31> Signature
for Aggressive-Variant CRPC Predicts Platinum Sensitivity 


A molecular signature for aggressive-variant prostate carcinoma can predict
which men with castrate-resistant prostate cancer will benefit from
cabazitaxel with or without carboplatin. 


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c
05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31>  Read more  

 


  



  


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f
588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6>
Post-Progression Enzalutamide/Abiraterone Not Effective in Metastatic CRPC 


Continued enzalutamide with abiraterone failed to improve PFS in men with
metastatic castration-resistant prostate cancer who progressed on
enzalutamide alone. 


 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f
588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6>  Read more  

 


  



IN CASE YOU MISSED IT 

 


  



 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac6
78ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290>
Abiraterone/ADT Combo Increased Prostate Cancer Survival 



 image description here
<http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/
public/fizazi-100.jpg> 

Combined therapy with abiraterone acetate/prednisone plus ADT significantly
improved overall survival and radiographic progression-free survival among
men with metastatic hormone-naive prostate cancer.

 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac6
78ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290>  Read more  

 


  



 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4d
d4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753> STAMPEDE:
Abiraterone Slowed Progression of Advanced Prostate Cancer 



 image description here
<http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/
public/james-100.jpg> 

Abiraterone at the start of ADT for men with metastatic prostate cancer
significantly improved overall survival and failure-free survival, with
manageable toxicity.

 
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4d
d4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753>  Read more  

 


  

 

	
	

  

 
<http://click.email.cmpmedica-usa.com/open.aspx?ffcb10-fe6716797766077f7114-
fdbb1570736204787d10767d6c-feca15707d60027f-fe98157571670c7d77-fdf0157571650
4757d12757c-ffcf14> 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://artsservices.uwaterloo.ca/pipermail/hopespringpcsg/attachments/20170607/79e7f9ea/attachment-0001.html>